Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Die Diabetologie
Erschienen in: Die Diabetologie 2/2024

30.01.2024 | Typ-2-Diabetes | DDG Praxisempfehlungen

Therapie des Typ-2-Diabetes

verfasst von: Prof. Dr. med. Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald H. Klein, Dirk Müller-Wieland, Michael A. Nauck, Tobias Wiesner, Erhard Siegel

Erschienen in: Die Diabetologie | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Auszug

Auf der Webseite der Deutschen Diabetes Gesellschaft (https://​www.​ddg.​info/​behandlung-leitlinien/​leitlinien-praxisempfehlung​en) befinden sich alle PDF zum kostenlosen Download. …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
2.
3.
Schmidt C, Reitzle L, Dreß J et al (2020) Prävalenz und Inzidenz des dokumentierten Diabetes mellitus – Referenzauswertung für die Diabetes-Surveillance auf Basis von Daten aller gesetzlich Krankenversicherten. Bundesgesundheitsbl 63:93–102
4.
Tönnies T, Rathmann W (2021) Epidemiologie des Diabetes in Deutschland. In: Deutsche Diabetes Gesellschaft, diabetesDE – Deutsche Diabetes-Hilfe (Hrsg) Deutscher Gesundheitsbericht Diabetes 2022. Verlag Kirchheim, Mainz, S 9–15
5.
Tönnies T, Hoyer A, Brinks R et al (2023) Spatio-temporal trends in the incidence of type 2 diabetes in Germany—analysis of the claims data of 63 million persons with statutory health insurance from 2014 to 2019. Dtsch Ärztebl Int 120:173–179PubMedPubMedCentral
6.
Rosengren A, Dikaiou P (2023) Cardiovascular outcomes in type 1 and type 2 diabetes. Diabetologia 66:425–437PubMedPubMedCentral
7.
Dziopa K, Asselbergs FW, Gratton J et al (2022) Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings. Diabetologia 65:644–656PubMedPubMedCentral
8.
Alberti KGMM, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome. Circulation 120:1640–1645PubMed
9.
Heinemann L, Kaiser P, Freckmann G et al (2018) HbA1c-Messung in Deutschland: Ist die Qualität ausreichend für Verlaufskontrolle und Diagnose? Diabetologie 13:46–53
10.
Landgraf R, Nauck M, Freckmann G et al (2018) Fallstricke bei der Diabetesdiagnostik: Wird zu lax mit Laborwerten umgegangen? Dtsch Med Wochenschr 143:1549–1555PubMed
11.
Pleus S, Tytko A, Landgraf R et al (2023) Definition, klassifikation, diagnostik und differenzialdiagnostik des diabetes mellitus: update 2023. Diabetol Stoffwechs 18(Suppl. 02):S100–S113
12.
Landgraf R (2021) HbA1c in der Diabetesdiagnostik. Der Goldstandard? Diabetes Aktuell 19:22–29
13.
Ahlqvist E, Storm P, Käräjämäki A et al (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diabetes Endocrinol 6:361–369PubMed
14.
Zaharia OP, Strassburger K, Strom A, German Diabetes Study Group. et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recentonset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7:684–694PubMed
15.
Dennis JM, Shields BM, Henley WE et al (2019) Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes Endocrinol 7:442–451PubMedPubMedCentral
16.
Elwyn G, Vermunt NPCA (2020) Goal-based shared decision-making: developing an integrated model. J Patient Exp 7:688–696PubMed
17.
Wang R, Song Y, Yan Y et al (2016) Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis. Atherosclerosis 254:193–199PubMed
18.
Mach F, Baigent C, Catapano AL, ESC Scientific Document Group et al (2020) 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41:111–188PubMed
19.
Parhofer KG, Birkenfeld AL, Krone W et al (2023) Lipidtherapie bei patienten mit diabetes mellitus. Diabetol Stoffwechs 18(Suppl. 02):S330–S336
20.
Jordan J, Kurschat C, Reuter C, Hypertonie A (2018) Diagnostik und Therapie. Dtsch Ärztebl Int 115:557–568PubMedPubMedCentral
21.
Whelton PK, Carey RM, Aronow WS et al (2018) ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 71:2199–2269PubMed
22.
Williams B, Mancia G, Spiering W et al (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 39:3021–3104PubMed
23.
24.
Han H, Cao Y, Feng C et al (2022) Association of a healthy lifestyle with all-cause and cause-specific mortality among individuals with type 2 diabetes: a prospective study in UK biobank. Diabetes Care 45:319–329PubMed
25.
Zhang Y, Pan XF, Chen J et al (2020) Combined lifestyle factors and risk of incident type 2 diabetes and prognosis among individuals with type 2 diabetes: a systematic review and meta-analysis of prospective cohort studies. Diabetologia 63:21–3316PubMed
26.
Kivimäki M, Bartolomucci A, Kawachi I (2023) The multiple roles of life stress in metabolic disorders. Nat Rev Endocrinol 19:10–27PubMed
27.
Lloyd-Jones DM, Allen NB, Anderson CAM et al (2022) Life’s essential 8: updating and enhancing the American heart association’s construct of cardiovascular health: a presidential advisory from the American heart association. Circulation 146:e18–e43PubMedPubMedCentral
28.
29.
Hermanns N, Ehrmann D, Shapira A et al (2022) Coordination of glucose monitoring, self-care behaviour and mental health: achieving precision monitoring in diabetes. Diabetologia 65:1883–1894PubMedPubMedCentral
30.
Sherr JL, Heinemann L, Fleming A et al (2023) Automated insulin delivery: benefits, challenges, and recommendations. A consensus report of the joint diabetes technology working group of the European association for the study of diabetes and the American diabetes association. Diabetologia 66:3–22PubMed
31.
Oliver N, Chow E, Luk AOY et al (2023) Applications of continuous glucose monitoring across settings and populations: report from the 23rd Hong Kong diabetes and cardiovascular risk factors—East meets west symposium. Diabet Med 40:e15038PubMed
32.
Daly A, Howorka R (2021) Technology in the management of type 2 diabetes—present status and future prospects. Diabetes Obes Metab 23:1722–1732PubMedPubMedCentral
33.
Di Molfetta S, Caruso I, Cignarelli A et al (2023) Professional continuous glucose monitoring in patients with diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 25:1301–1310PubMed
34.
Forouhi NG, Misra A, Mohan V et al (2018) Dietary and nutritional approaches for prevention and management of type 2 diabetes. BMJ 361:k2234PubMedPubMedCentral
35.
Serra-Majem L, Román-Viñas B, Sanchez-Villegas A et al (2019) Benefits of the Mediterranean diet: epidemiological and molecular aspects. Mol Aspects Med 67:1–55PubMed
36.
Taylor R, Al-Mrabeh A, Sattar N (2019) Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol 7:726–736PubMed
37.
Evert AB, Dennison M, Gardner CD et al (2019) Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care 42:731–754PubMedPubMedCentral
38.
Hauner H (2021) Evidenz in der Ernährungstherapie des Diabetes mellitus. Diabetologe 17:687–696
39.
Tombeck A (2023) Rolle der Ballaststoffe in der Ernährung von Menschen mit Typ-2-Diabetes. Info Diabetol 17:31–36
40.
Carlström M, Larsson SC (2018) Coffee consumption and reduced risk of developing type 2 diabetes: a systematic review with meta-analysis. Nutr Rev 76:395–417PubMed
41.
Di Maso M, Boffetta P, Negri E et al (2021) Caffeinated coffee consumption and health outcomes in the US population: a dose–response meta-analysis and estimation of disease cases and deaths avoided. Adv Nutr 12:1160–1176PubMedPubMedCentral
42.
Larsson SC, Woolf B, Gill D (2023) Appraisal of the causal effect of plasma caffeine on adiposity, type 2 diabetes, and cardiovascular disease: two sample mendelian randomisation study. BMJ Med 2:e335
43.
Chester B, Babu JR, Greene MW et al (2019) The effects of popular diets on type 2 diabetes management. Diabetes Metab Res Rev 35:e3188PubMed
44.
Naude CE, Brand A, Schoonees A et al (2022) Low-carbohydrate versus balanced carbohydrate diets for reducing weight and cardiovascular risk (review). Cochrane Database Syst Rev 1:CD13334PubMed
45.
Patikorn C, Roubal K, Sajesh KV et al (2021) Intermittent fasting and obesity-related health outcomes. An umbrella review of meta-analyses of randomized clinical trials. JAMA Netw Open 4:e2139558PubMedPubMedCentral
46.
Uldal S, Clemmensen KKB, Persson F et al (2022) Is time-restricted eating safe in the treatment of type 2 diabetes? A review of intervention studies. Nutrients 14:2299PubMedPubMedCentral
47.
Shan Z, Wang F, Li Y et al (2023) Healthy eating patterns and risk of total and cause-specific mortality. JAMA Intern Med 183:142–153PubMed
48.
Churuangsuk C, Hall J, Reynolds A et al (2022) Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia 65:14–36PubMed
49.
The Diabetes and Nutrition Study Group (DNSG), European Association for the Study of Diabetes (EASD) (2023) Evidence-based European recommendations for the dietary management of diabetes. Diabetologia 66:965–985
50.
Salas-Salvadó J, Díaz-López A, Ruiz-Canela M et al (2019) Effect of a lifestyle intervention program with energy-restricted mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-plus trial. Diabetes Care 42:777–788PubMed
51.
Thackrey E, Chen J, Martino CR et al (2022) The effects of diet on weight and metabolic outcomes in patients with double diabetes: a systematic review. Nutrition 94:111536PubMed
52.
Kempf K, Altpeter B, Berger J et al (2017) Efficacy of the telemedical lifestyle intervention program TeLiPro in advanced stages of type 2 diabetes: a randomized controlled trial. Diabetes Care 40:863–871PubMed
53.
Lean MEJ, Leslie WS, Barnes AC et al (2019) Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2‑year results of the DiRECT open-label, cluster-randomized trial. Lancet Diabetes Endocrinol 7:344–355PubMed
54.
Adipositas – Prävention und Therapie. AWMF-Register Nr. 050-001.
55.
Cassidy S, Trenell M, Stefanetti RJ et al (2023) Physical activity, inactivity and sleep during the Diabetes Remission Clinical Trial (DiRECT). Diabet Med 40:e15010PubMed
56.
Aberle J, Lautenbach A, Meyhöfer S et al (2023) Adipositas und Diabetes. Diabetol Stoffwechs 18(Suppl. 02):S305–S313
57.
Yang D, Yang Y, Li Y et al (2019) Physical exercise as therapy for type 2 diabetes mellitus: from mechanism to orientation. Ann Nutr Metab 74:313–321PubMed
58.
Tarp J, Støle AP, Blond K et al (2019) Cardiorespiratory fitness, muscular strength and risk of type 2 diabetes: a systematic review and metaanalysis. Diabetologia 62:1129–1142PubMedPubMedCentral
59.
Liu Y, Ye W, Chen Q et al (2019) Resistance exercise intensity is correlated with attenuation of HbA1c and insulin in patients with type 2 diabetes: a systematic review and meta-analysis. Int J Environ Res Public Health 16:140PubMedPubMedCentral
60.
Kanaley JA, Colberg SR, Corcoran MH et al (2022) Exercise/Physical activity in individuals with type 2 diabetes: a consensus statement from the American college of sports medicine. Med Sci Sports Exerc 54:353–368PubMedPubMedCentral
61.
Esefeld K, Kress S, Behrens M et al (2021) Diabetes, sport und Bewegung. Diabetol Stoffwechs 16(Suppl. 02):S299–S307
62.
Jabardo-Camprubí G, Donat-Roca R, Sitjà-Rabert M et al (2020) Drop-out ratio between moderate to high-intensity physical exercise treatment by patients with, or at risk of, type 2 diabetes mellitus: a systematic review and meta-analysis. Physiol Behav 215:112786PubMed
63.
Villafranca Cartagena M, Tort-Nasarre G, Rubinat Arnaldo E (2021) Barriers and facilitators for physical activity in adults with type 2 diabetes mellitus: a scoping review. Int J Environ Res Public Health 18:5359
64.
MacDonald CS, Ried-Larsen M, Soleimani J et al (2021) A systematic review of adherence to physical activity interventions in individuals with type 2 diabetes. Diabetes Metab Res Rev 37:e3444PubMed
65.
Thomsen S, Kristensen GDW, Jensen NWH et al (2021) Maintaining changes in physical activity among type 2 diabetics—a systematic review of rehabilitation interventions. Scand J Med Sci Sports 31:1582–1591PubMed
66.
Pan A, Wang Y, Talaei M et al (2015) Relation of active, passive, and quitting smoking with incident diabetes: a meta-analysis and systematic review. Lancet Diabetes Endocrinol 3:958–996PubMedPubMedCentral
67.
Kar D, Gillies C, Nath M et al (2019) Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 56:839–850PubMedPubMedCentral
68.
Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung. S3-Leitlinie Langversion AWMF-Register Nr. 076-006.
69.
70.
Concato J, Corrigan-Curay J (2022) Real-world evidence—where are we now? N Engl J Med 386:1680–1682PubMed
71.
Fleming GA, Petrie JR, Bergenstal RM et al (2020) Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetes Care 43:250–260PubMed
72.
Khunti K, Gomes MB, Pocock S et al (2018) Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: a systematic review. Diabetes Obes Metab 20:427–437PubMed
73.
Matthews DR, Paldánius PM, Proot P, VERIFY study group et al (2019) Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomized, double-blind trial. Lancet 394:1519–1529PubMed
74.
Meier JJ (2021) Efficacy of semaglutide in a subcutaneous and an oral formulation. Front Endocrinol 12:645617
75.
Gallwitz B, Giorgino F (2021) Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide. Front Endocrinol 12:645507
76.
Zaazouee MS, Hamdallah A, Helmy SK et al (2022) Semaglutide for the treatment of type 2 diabetes mellitus: a systematic review and network meta-analysis of safety and efficacy outcomes. Diabetes Metab Syndr 16:102511PubMed
77.
Alhindi Y, Avery A (2022) The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP‑1 RA comparators: a systematic review and network meta-analysis. Contemp Clin Trials Commun 28:100944PubMedPubMedCentral
78.
Gough SC, Bode B, Woo V et al (2014) Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. Lancet Diabetes Endocrinol 2:885–893PubMed
79.
Diamant M, Nauck MA, Shaginian R et al (2014) Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 37:2763–2773PubMed
80.
Montvida O, Klein K, Kumar S et al (2017) Addition of or switch to insulin therapy in people treated with glucagon-like peptide‑1 receptor agonists: a real-world study in 66 583 patients. Diabetes Obes Metab 19:108–117PubMed
81.
Gomez-Peralta F, Al-Ozairi E, Jude EB et al (2021) Titratable fixed-ratio combination of basal insulin plus a glucagon-like peptide‑1 receptor agonist: a novel, simplified alternative to premix insulin for type 2 diabetes. Diabetes Obes Metab 23:1445–1452PubMedPubMedCentral
82.
Edelman S, Cassarino D, Kayne D et al (2022) Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist. J Manag Care Spec Pharm 28:958–968PubMed
83.
Champlain JM (2022) Practical considerations for use of insulin/glucagon-like peptide 1 receptor agonist combinations in older adults with type 2 diabetes. J Fam Pract 71(06):S34–S39PubMed
84.
Mehta R, Billings LK, Liebl A et al (2022) Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide‑1 receptor agonist in people with type 2 diabetes. Diabet Med 39:e14901PubMedPubMedCentral
85.
Risovic I, Dumanovic MS, Bojic M et al (2023) Direct comparison two fixed-ratio combination glucagon-like peptide receptor agonist and basal insulin on glycemic and non glycemic parameters in type 2 diabetes. BMC Endocr Disord 23:28PubMedPubMedCentral
86.
Home PD, McCrimmon RJ, Rosenstock J, SoliMix trial investigators et al (2023) Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics. Diabetes Obes Metab 25:656–663PubMed
87.
Visolyi GÁ, Domján BA, Svébis MM et al (2023) Comparison of efficacy and safety of commercially available fixed-ratio combinations of insulin degludec/liraglutide and insulin glargine/lixisenatide: a network meta-analysis. Can J Diabetes 47:368–377PubMed
88.
Daly AB, Boughton CK, Nwokolo M et al (2023) Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nat Med 29:203–208PubMedPubMedCentral
89.
Karol AB, O’Malley G, Fallurin R et al (2023) Automated insulin delivery systems as a treatment for type 2 diabetes Mellitus: a review. Endocr Pract 29:214–220PubMed
90.
Davis GM, Peters AL, Bode BW et al (2023) Safety and efficacy of the omnipod 5 automated insulin delivery system in adults with type 2 diabetes: from injections to hybrid closed-loop therapy. Diabetes Care 46:742–750PubMedPubMedCentral
91.
Averna M, Catapano AL (2022) One year after the ESC/EAS guidelines on cholesterol control. What’s the new evidence? What’s missing? Eur J Intern Med 95:1–4PubMed
92.
Mengden T, Weisser B (2021) Therapieüberwachung bei arterieller hypertonie. Dtsch Arztebl 118:473–478
93.
Banegas JR, Ruilope LM, de la Sierra A et al (2018) Relationship between clinic and ambulatory blood-pressure measurements and mortality. N Engl J Med 378:1509–1520PubMed
94.
95.
American Diabetes Association (2021) Cardiovascular disease and risk management: standards of medical care in diabetes—2021. Diabetes Care 44(Suppl. 01):S125–S150
96.
The SPRINT Research Group. (2015) A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373:2103–2116PubMedCentral
97.
The SPRINT Research Group. (2021) Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 384:1921–1930PubMedCentral
98.
Busch M, Wanner C, Wolf G (2023) KDIGO-Leitlinie zur Behandlung des Diabetes mellitus bei chronischer Nierenerkrankung – update 2022. Nephrologie 18:160–170
99.
ElSayed NA, Aleppo G, Aroda VR et al (2023) Chronic kidney disease and risk management: standards of care in diabetes—2023. Diabetes Care 46(Suppl. 01):S191–S202PubMed
100.
Merker L, Bautsch BW, Ebert T et al (2023) Nephropathie bei Diabetes. Diabetol Stoffwechs 18(Suppl. 02):S342–S347
101.
The Nuffield Department of Population Health Renal Studies Group*, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium (2022) Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400:1788–1801
102.
Neuen BL, Young T, Heerspink HJL et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7:845–854PubMed
103.
Giugliano D, Longo M, Signoriello S et al (2022) The effect of DPP-4 inhibitors, GLP‑1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovasc Diabetol 21:42PubMedPubMedCentral
104.
Mannucci E, Gallo M, Giaccari A et al (2023) Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: an updated meta-analysis of randomized controlled trials with external adjudication of events. Diabetes Obes Metab 25:444–453PubMed
105.
Zhang Y, Jiang L, Wang J et al (2022) Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP‑1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol 21:232PubMedPubMedCentral
106.
Singh AK, Singh A, Singh R et al (2022) Finerenone in diabetic kidney disease: a systematic review and critical appraisal. Diabetes Metab Syndr 16:102638PubMed
107.
Shi Q, Nong K, Vandvik PO et al (2023) Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 381:e74068PubMedPubMedCentral
108.
Stefan N, Roden M (2023) Diabetes und Fettleber. Diabetol Stoffwechs 18(Suppl. 02):S324–S329
109.
Roeb E, Canbay A, Bantel H et al Aktualisierte S2k-Leitlinie Nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) April 2022 – AWMF-Registernummer: 021-025.
110.
Lawall H, Huppert P, Rümenapf G et al. Periphere arterielle Verschlusskrankheit (PAVK), Diagnostik, Therapie und Nachsorge. AWMF-Register Nr. 065-003 2015. (gültig bis 29.11.2020, in Überarbeitung)
111.
Ziegler D, Tesfaye S, Spallone V et al (2022) Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: international expert consensus recommendations. Diabetes Res Clin Pract 186:109063PubMed
112.
113.
114.
Roeb E, Steffen HM, Bantel H et al Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) April 2022 – AWMF-Registernummer: 021-025.
115.
Gill D, Cameron AC, Burgess S et al (2021) Urate, blood pressure, and cardiovascular disease. Evidence from mendelian randomization and meta-analysis of clinical trials. Hypertension 77:383–392PubMed
116.
117.
118.
El Sayed NA, Aleppo G, American Diabetes Association (2023) Chronic kidney disease and risk management: standards of care in diabetes—2023. Diabetes Care 46(Suppl 1):S191–S202PubMed
119.
The Look AHEAD Research Group (2013) Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369:145–154PubMedCentral
120.
Unick JL, Gaussoin SA, Hill JO et al (2017) Objectively assessed physical activity and weight loss maintenance among individuals enrolled in a lifestyle intervention. Obesity 25:1903–1909
121.
The Look AHEAD Research Group (2016) Association of the magnitude of weight loss and changes in physical fitness with longterm cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the look AHEAD randomized clinical trial. Lancet Diabetes Endocrinol 4:913–921
122.
Gregg EW, Lin J, Bardenheier B et al (2018) Impact of intensive lifestyle intervention on disability-free life expectancy: the look AHEAD study. Diabetes Care 41:1040–1048PubMedPubMedCentral
123.
Chao AM, Wadden TA, Berkowitz RI, Look AHEAD Research Group et al (2020) Weight change 2 years after termination of the intensive lifestyle intervention in the look AHEAD study. Obesity 28:893–890PubMed
124.
125.
Thomsen S, Westergaard Kristensen GD, Weigelt N et al (2021) Maintaining changes in physical activity among type 2 diabetics—a systematic review of rehabilitation interventions. Scand J Med Sci Sports 31:1582–1591PubMed
126.
Jansson AK, Chan LX, Lubans DR et al (2022) Effect of resistance training on HbA1c in adults with type 2 diabetes mellitus and the moderating effect of changes in muscular strength: a systematic review and meta-analysis. BMJ Open Diab Res Care 10:e2595PubMedPubMedCentral
127.
Balducci S, Haxhi J, Sacchetti M et al (2022) Relationships of changes in physical activity and sedentary behavior with changes in physical fitness and cardiometabolic risk profile in individuals with type 2 diabetes: the Italian Diabetes and Exercise Study 2 (IDES_2). Diabetes Care 45:213–221PubMed
128.
Lazarus B, Wu A, Shin JI et al (2018) Association of metformin use with risk of lactic acidosis across the range of kidney function. A community-based cohort study. JAMA Intern Med 178:903–910PubMedPubMedCentral
129.
Griffin SJ, Leaver JK, Irving GJ et al (2017) Impact of metformin on cardiovascular disease: a meta-analysis of randomized trails among people with type 2 diabetes. Diabetologia 60:1620–1629PubMedPubMedCentral
130.
Palmer SC, Mavridis D, Nicolucci A et al (2016) Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes. A meta-analysis. JAMA 316:313–324PubMed
131.
Madsen KS, Kähler P, Kähler LKA et al (2019) Metformin and secondor third generation sulphonylurea combination therapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 4:CD12368PubMed
132.
Sattar N, McGuire DK (2021) Prevention of CV outcomes in antihyperglycemic drug-naive patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. Eur Heart J 42:2574–2576PubMed
133.
Schernthaner G, Brand K, Bailey CJ (2022) Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism 130:155160PubMed
134.
Gonzalez-Gonzalez JG, Solis RC, Gonzalez-Colmenero AD et al (2022) Effect of metformin on microvascular outcomes in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 186:109821PubMedCentral
135.
Lee CG, Heckman-Stoddard B, Dabelea D et al (2021) Effect of Metformin and lifestyle interventions on mortality in the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care 44:2775–2782PubMedPubMedCentral
136.
Tan J, Wang Y, Liu S et al (2021) Long-acting metformin vs. Metformin immediate release in patients with type 2 diabetes: a systematic review. Front Pharmacol 12:669814PubMedPubMedCentral
137.
Mallik R, Chowdhury TA (2018) Metformin in cancer. Diabetes Res Clin Pract 143:409–419PubMed
138.
Thakur S, Daley B, Klubo-Gwiezdzinska J (2019) The role of the antidiabetic drug metformin in the treatment of endocrine tumors. J Mol Endocrinol 63:R17–R35PubMedPubMedCentral
139.
De A, Kuppusamy G (2020) Metformin in breast cancer: preclinical and clinical evidence. Curr Probl Cancer 44:100488PubMed
140.
Rahmani J, Manzari N, Thompson J et al (2020) The effect of metformin on biomarkers associated with breast cancer outcomes: a systematic review, meta-analysis, and dose-response of randomized clinical trials. Clin Transl Oncol 22:37–49PubMed
141.
Fong W, To KKW (2020) Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cell Mol Life Sci 76:3383–3406
142.
Aljofan M, Riethmacher D (2019) Anticancer activity of metformin: a systematic review of the literature. Future Sci OA 5:FSO410PubMedPubMedCentral
143.
Feng Z, Zhou X, Liu N et al (2019) Metformin use and prostate cancer risk: a meta-analysis of cohort studies. Medicine 98:e14955PubMedPubMedCentral
144.
Lv Z, Guo Y (2020) Metformin and its benefits for various diseases. Front Endocrinol 11:191
145.
Prodromidou A, Lekka S, Fotiou A et al (2021) The evolving role of targeted metformin administration for the prevention and treatment of endometrial cancer: a systematic review and meta-analysis of randomized controlled trials. J Gynecol Obstet Hum Reprod 50:102164PubMed
146.
Triggle CR, Mohammed I, Bshesh K et al (2022) Metformin: is it a drug for all reasons and diseases? Metabolism 133:155223PubMed
147.
Wang Q, Shi M (2022) Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis. Anticancer Drugs 33:191–199PubMed
148.
Matarese G (2023) The link between obesity and autoimmunity overnutrition could lead to loss of self-tolerance by impinging on immune regulation. Science 379:1298–1300ADSPubMed
149.
Wensink MJ, Lu Y, Tian L (2022) Preconception antidiabetic drugs in men and birth defects in offspring. A nationwide cohort study. Ann Intern Med 175:665–673PubMedPubMedCentral
150.
Khunti K, Knighton P, Zaccardi F et al (2021) Prescription of glucose lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol 9:293–303PubMedPubMedCentral
151.
Steenblock C, Schwarz PEH, Ludwig B et al (2021) COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol 9:786–798PubMedPubMedCentral
152.
Bornstein SR, Rubino F, Khunti K et al (2020) Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 8:546–550PubMedPubMedCentral
153.
Wargny M, Potier L, Gourdy P et al (2021) Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. Diabetologia 64:778–794PubMedPubMedCentral
154.
Kow CS, Hasan SS (2021) Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: a meta-analysis. J Med Virol 93:695–697PubMed
155.
Lim S, Bae JH, Kwon H‑S, Nauck MA (2021) COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 17:11–30PubMed
156.
Oshima M, Jun M, Ohkuma T et al (2019) The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. Diabetologia 62:1988–1997PubMedPubMedCentral
157.
The ADVANCE Collaborative Group. (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
158.
Rosenstock J, Kahn SE, Johansen OE, CAROLINA Investigators et al (2019) Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322:1155–1116PubMed
159.
Rados DV, Pinto LC, Remonti LR et al (2016) The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials. PLoS Med 13:e1001992
160.
Azoulay L, Suissa S (2017) Sulfonylureas and the risks of cardiovascular events and death: a methodological meta-regression analysis of the observational studies. Diabetes Care 40:706–714PubMed
161.
Bain S, Druyts E, Balijepalli C et al (2017) Cardiovascular events and all-cause mortality associated with sulphonylureas compared with other antihyperglycaemic drugs: a bayesian meta-analysis of survival data. Diabetes Obes Metab 19:329–335PubMed
162.
Zhuang XD, He X, Yang DY et al (2018) Comparative cardiovascular outcomes in the era of novel anti-diabetic agents: a comprehensive network meta-analysis of 166 371 participants from170 randomized controlled trials. Cardiovasc Diabetol 17:79PubMedPubMedCentral
163.
Powell WR, Christiansen CL, Miller DR (2018) Meta-analysis of sulfonylurea therapy on long-term risk of mortality and cardiovascular events compared to other oral glucose-lowering treatments. Diabetes Ther 9:1431–1440PubMedPubMedCentral
164.
Simpson SH, Lee J, Choi S et al (2015) Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 3:43–51PubMed
165.
Hemmingsen B, Schroll JB, Lund SS et al (2013) Sulphonylurea monotherapy for patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 4:CD9008
166.
Hemmingsen B, Schroll JB, Jorn Wetterslev J et al (2014) Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysis. CMAJ Open 2:E162–E175PubMedPubMedCentral
167.
Vaccaro O, Masulli M, Nicolucci M et al (2017) Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomized, multicenter trial. Lancet Diabetes Endocrinol 5:887–897PubMed
168.
Ogundipe O, Mazidi M, Chin KL et al (2021) Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes. Acta Diabetol 58:39–46PubMed
169.
Khan MS, Solomon N, DeVore AD (2022) Clinical outcomes with metformin and sulfonylurea therapies among patients with heart failure and diabetes. JACC Heart Fail 10:198–210PubMed
170.
Volke V, Katus U, Johannson A et al (2022) Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs. BMC Endocr Disord 22:251PubMedPubMedCentral
171.
Wang H, Cordiner RLM, Huangm Y et al (2023) Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nation-wide population-based comparative safety study. Diabetes Care 46:967–977PubMedPubMedCentral
172.
Davies MJ, Aroda VR, Collins BS et al (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45:2753–2786PubMedPubMedCentral
173.
Chen K, Kang D, Yu M et al (2018) Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: a meta-analysis of long-term randomized controlled trials. Diabetes Obes Metab 20:1029–1033PubMed
174.
Patorno E, Schneeweiss S, Gopalakrishnan C et al (2019) Using real world data to predict findings of an ongoing phase IV cardiovascular outcome trial: cardiovascular safety of linagliptin versus glimepiride. Diabetes Care 42:2204–2210PubMedPubMedCentral
175.
Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326PubMed
176.
White WB, Cannon CP, Heller SR et al (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335PubMed
177.
Green JB, Bethel MA, Armstrong PW, TECOS Study Group et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242PubMed
178.
Rosenstock J, Perkovic V, Johansen OE et al (2019) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321:69–79PubMed
179.
Perkovic V, Toto R, Cooper ME et al (2020) Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: secondary analysis of the CARMELINA randomized trial. Diabetes Care 43:1803–1812PubMedPubMedCentral
180.
Monami M, Ahrén B, Dicembrini I et al (2013) Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15:112–120PubMed
181.
Xu S, Zhang X, Tang L et al (2017) Cardiovascular effects of dipeptidylpeptidase‑4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review. Postgrad Med 129:205–215PubMed
182.
Zheng SL, Roddick AJ, Aghar-Jaffar R et al (2018) Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all cause mortality in patients with type 2 diabetes. A systematic review and meta-analysis. JAMA 319:1580–1591PubMedPubMedCentral
183.
Ling J, Cheng P, Ge L et al (2019) The efficacy and safety of dipeptidyl peptidase- 4 inhibitors for type 2 diabetes: a bayesian network meta-analysis of 58 randomized controlled trials. Acta Diabetol 56:249–272PubMed
184.
Li L, Li S, Deng K et al (2016) Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies. BMJ 352:i610PubMedPubMedCentral
185.
Guo WQ, Li L, Su Q et al (2017) Effect of dipeptidylpeptidase-4 inhibitors on heart failure: a network meta-analysis. Value Health 20:1427–1430PubMed
186.
Nauck MA, Meier JJ, Cavender MA et al (2017) Cardiovascular actions and clinical outcomes with glucagon-like peptide‑1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 136:849–870PubMed
187.
Sinha B, Ghosal S (2019) Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure. Diabetes Res Clin Pract 150:8–16PubMed
188.
Xie Y, Bowe B, Gibson AK et al (2020) Comparative effectiveness of SGLT2 inhibitors, GLP‑1 receptor agonists, DPP‑4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care 43:2859–2869PubMed
189.
Kanie T, Mizuno A, Takaoka Y et al (2021) Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 10:CD13650PubMed
190.
The GRADE Study Research Group (2022) Glycemia reduction in type 2 diabetes—glycemic outcomes. N Engl J Med 387:1063–1074
191.
The GRADE Study Research Group (2022) Glycemia reduction in type 2 diabetes—microvascular and cardiovascular outcomes. N Engl J Med 387:1075–1088
192.
Dougherty J, Guirguis E, Thornby KA et al (2021) A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann Pharmacother 55:65–79PubMed
193.
Kumar J, Memon RS, Shahid I et al (2021) Antidiabetic drugs and nonalcoholic fatty liver disease: a systematic review, meta-analysis and evidence map. Dig Liver Dis 53:44–51PubMed
194.
Koufakis T, Mustafa OG, Zebekakis P et al (2020) Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close. Diabet Med 37:1418–1426PubMed
195.
Du H, Wang DW, Chen C (2020) The potential effects of DPP-4 inhibitors on cardiovascular system in COVID-19 patients. J Cell Mol Med 24:10274–10278PubMedPubMedCentral
196.
Bonora BM, Avogaro A, Fadini GP (2021) Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. J Endocrinol Invest 44:1379–1386PubMedPubMedCentral
197.
Yang Y, Cai Z, Zhang J (2021) DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: a meta-analysis. PLoS ONE 16:e251916PubMedPubMedCentral
198.
Nguyen NN, Ho DS, Nguyen HS et al (2022) Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: a meta-analysis. Metabolism 131:155196PubMedPubMedCentral
199.
Tkáč I, Raz I (2017) Combined analysis of three large interventional trials with gliptins indicates increased incidence of acute pancreatitis in patients with type 2 diabetes. Diabetes Care 40:284–286PubMed
200.
Pinto LC, Rados DV, Barkann SS et al (2018) Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep 8:782ADSPubMedPubMedCentral
201.
Tasanen K, Varpuluoma O, Nishie W (2019) Dipeptidyl peptidase‑4 inhibitor-associated bullous pemphigoid. Front Immunol 10:1238PubMedPubMedCentral
202.
Overbeek JA, Bakker M, van der Heijden AAWA et al (2018) Risk of dipeptidyl peptidase‑4 (DPP-4) inhibitors on site specific cancer: a systematic review and meta-analysis. Diabetes Metab Res Rev 34:e3004PubMed
203.
Dicembrini I, Montereggi C, Nreu B et al (2020) Pancreatitis and pancreatic cancer in patientes treated with dipeptidyl peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 159:107981PubMed
204.
Abrahami D, Douros A, Yin H et al (2018) Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study. BMJ 360:k872PubMedPubMedCentral
205.
Li G, Crowley MJ, Tang H et al (2019) Dipeptidyl peptidase 4 inhibitors and risk of inflammatory bowel disease among patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care 42:e119–e121PubMedPubMedCentral
206.
Radel JA, Pender DN, Shah SA (2019) Dipeptidyl peptidase‑4 inhibitors and inflammatory bowel disease risk: a meta-analysis. Ann Pharmacother 53:697–704PubMed
207.
He L, Wang J, Ping F et al (2022) Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. BMJ 377:e68882PubMedPubMedCentral
208.
Storgaard H, Gluud LL, Bennett C et al (2016) Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis. PLoS ONE 11:e166125PubMedPubMedCentral
209.
Monami M, Liistro F, Scatena A et al (2018) Short and medium-term efficacy of sodium glucose co-transporter‑2 (SGLT-2) inhibitors: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 20:1213–1222PubMed
210.
Usman MS, Siddiqi TJ, Memon MM et al (2018) Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol 25:495–502PubMed
211.
Mishriky BM, Tanenberg RJ, Sewell KA et al (2018) Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 44:112–120PubMed
212.
Seidu S, Kunutsor SK, Cos X et al (2018) SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: a systematic review and meta-analysis. Prim Care Diabetes 12:265–283PubMed
213.
Rådholm K, Wu JH, Wong MG et al (2018) Effects of sodium-glucose cotransporter- 2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes—a systematic review. Diabetes Res Clin Pract 140:118–128PubMed
214.
Aronson R, Frias J, Goldman A et al (2018) Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DMdespite diet and exercise: VERTIS MONO extension study. Diabetes Obes Metab 20:1453–1460PubMedPubMedCentral
215.
Hollander P, Hill J, Johnson J et al (2019) Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on Metformin. Curr Med Res Opin 35:1335–1343PubMed
216.
Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39PubMed
217.
Zaman M, Memon RS, Amjad A et al (2020) Effect of ertugliflozin on glycemic levels, blood pressure and body weight of patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Diabetes Metab Disord 19:1873–1878PubMedPubMedCentral
218.
Tsapas A, Karagiannis T, Kakotrichi P et al (2021) Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diabetes Obes Metab 23:2116–2124PubMed
219.
Täger T, Atar D, Agewall S et al (2021) Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Heart Fail Rev 26:1421–1435PubMed
220.
Liu L, Shi FH, Xu H et al (2022) Efficacy and safety of ertugliflozin in type 2 diabetes: a systematic review and meta-analysis. Front Pharmacol 12:752440PubMedPubMedCentral
221.
Duan XY, Liu SY, Yin DG (2021) Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: a network meta-analysis based on cardiovascular or renal outcome trials. Medicine 100:e26431PubMedPubMedCentral
222.
Braunwald E (2022) Gliflozins in the management of cardiovascular disease. N Engl J Med 386:2024–2034PubMed
223.
Puckrin R, Saltiel MP, Reynier P et al (2018) SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 55:503–514PubMed
224.
Lega IC, Bronskill SE, Campitelli MA et al (2019) Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab 21:2394–2404PubMed
225.
Dave CV, Schneeweiss S, Patorno E (2019) Comparative risk of genital infections associated with sodium glucose co-transporter-2 inhibitors. Diabetes Obes Metab 21:434–438PubMed
226.
McGovern AP, Hogg M, Shields BM et al (2020) Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diab Res Care 8:e1238PubMedPubMedCentral
227.
Engelhardt K, Ferguson MK, Rosselli JL (2021) Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors. Ann Pharmacother 55:543–548PubMed
228.
Ge S, Liu R, Mao Y et al (2023) Safety of SGLT2 inhibitors in three chronic diseases. Int Heart J 64:246–251PubMed
229.
Yang JY, Wang T, Pate V et al (2020) Real-world evidence on sodium2glucose cotransporter‑2 inhibitor use and risk of fournier’s gangrene. BMJ Open Diab Res Care 8:e985PubMedPubMedCentral
230.
Silverii GA, Dicembrini I, Monami M et al (2020) Fournier’s gangrene and sodium-glucose co-transporter-2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 22:272–275PubMed
231.
Neal B, Perkovic V, Mahaffey KW, CANVAS Program Collaborative Group. et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657PubMed
232.
Huang CY, Lee JK (2020) Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals. Diabetes Obes Metab 22:2348–2355PubMed
233.
Bai Y, Jin J, Zhou W et al (2021) The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 31:1365–1374PubMed
234.
Paul SK, Bhatt DL, Montvida O (2021) The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study. Eur Heart J 42:1728–1738PubMed
235.
Ruanpeng D, Ungprasert P, Sangtian J et al (2017) Sodium-glucose cotransporter 2 (SGLT2) inhibitors and fracture risk in patients with type 2 diabetes mellitus: a meta-analysis. Diabetes Metab Res Rev 33:e2903
236.
Tang HL, Li DD, Zhang JJ et al (2016) Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab 18:1199–1206PubMed
237.
Li X, Li T, Cheng Y et al (2019) Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated metaanalysis. Diabetes Metab Res Rev 35:e3170PubMed
238.
Hidayat K, Du X, Shi BM (2019) Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide‑1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies. Osteoporos Int 30:1923–1940PubMed
239.
Zhuo M, Hawley CE, Paik JM et al (2021) Association of sodium-glucose cotransporter‑2 inhibitors with fracture risk in older adults with type 2 diabetes. JAMA Netw Open 4:e2130762PubMedPubMedCentral
240.
Fralick M, Schneeweiss S, Patorno E (2017) Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376:2300–2303PubMed
241.
Monami M, Nreu B, Zannoni S et al (2017) Effects of SGLT2 inhibitors on diabetic ketoacidosis: a meta-analysis of randomised controlled trials. Diabetes Res Clin Pract 130:53–60PubMed
242.
Fadini GP, Bonora BM, Avogaro A (2017) SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia 60:1385–1389PubMed
243.
Liu J, Li L, Li S et al (2020) Sodium-glucose co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 22:1619–1627PubMed
244.
Lin DS, Lee JK, Chen WJ (2021) Clinical Adverse Events Associated with Sodium-Glucose Cotransporter 2 Inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab 106:2133–2145PubMed
245.
Thiruvenkatarajan V, Meyer EJ, Nanjappa N et al (2019) Perioperative diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitors: a systematic review. Br J Anaesth 123:27–e36PubMed
246.
Milder DA, Milder TY, Kam PCA (2018) Sodium-glucose co-transporter type-2 inhibitors: pharmacology and perioperative considerations. Anaesthesia 73:1008–1018PubMed
247.
Donnan K, Segar L (2019) SGLT2 inhibitors and metformin: dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes. Eur J Pharmacol 846:23–29PubMedPubMedCentral
248.
He G, Yang G, Huang X et al (2023) SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: a meta-analysis of randomized controlled trials. Heart Lung 59:109–116PubMed
249.
Aziri B, Begic E, Jankovic S et al (2023) Systematic review of sodium-glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure-related events. ESC Heart Fail 10:1499–1530PubMedPubMedCentral
250.
Ahmad Y, Madhavan MV, Stone GW et al (2022) Sodium-glucose cotransporter 2 inhibitors in patients with heart failure: a systematic review and meta-analysis of randomized trials. Eur Heart J Qual Care Clin Outcomes 8:383–390PubMed
251.
Vaduganathan M, Docherty KF, Claggett BL et al (2022) SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 400:757–767PubMed
252.
Marilly E, Cottin J, Cabrera N et al (2022) SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia 65:2000–2010PubMed
253.
Cao H, Rao X, Jia J et al (2023) Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 60:325–335PubMed
254.
Mannucci E, Gallo M, Giaccari A, SID-AMD joint panel for Italian Guidelines on Treatment of Type 2 Diabetes (2023) Effects of glucose-lowering agents on cardiovascular and renal outcomes in subjects with type 2 diabetes: an updated meta-analysis of randomized controlled trials with external adjudication of events. Diabetes Obes Metab 25:444–453PubMed
255.
Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357PubMed
256.
Mosenzon O, Wiviott SD, Cahn A et al (2019) Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 7:606–617PubMed
257.
Heerspink HJL, Stefánsson BV, Correa-Rotter R et al (2020) DAPA-CKD trial committees and investigators dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446PubMed
258.
Mosenzon O, Raz I, Wiviott SD et al (2022) Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes: post hoc analyses from the DECLARE-TIMI 58 trial. Diabetes Care 45:2350–2359PubMedPubMedCentral
259.
Furtado RHM, Bonaca MP, Raz I (2019) Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction. Circulation 139:2516–2527PubMed
260.
Kato ET, Silverman MG, Mosenzon O et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139:2528–2536PubMed
261.
Schechter M, Wiviott SD, Raz I et al (2023) Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. Lancet Diabetes Endocrinol 11:233–241PubMed
262.
McMurray JJV, Solomon SD, Inzucchi SE, DAPA-HF study et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008PubMed
263.
Nassif ME, Windsor SL, Borlaug BA et al (2021) The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nat Med 27:1954–1960PubMedPubMedCentral
264.
Wheeler DC, Stefánsson BV, Jongs N et al (2021) Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:22–31PubMed
265.
Waijer SW, Vart P, Cherney DZI et al (2022) Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial. Diabetologia 65:1085–1097PubMedPubMedCentral
266.
Kaze AD, Zhuo M, Seoyoung C et al (2022) Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 21:47PubMedPubMedCentral
267.
Solomon SD, McMurray JJV, Claggett et al (2022) Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 387:1089–1098PubMed
268.
Peikert A, Martinez FA, Vaduganathan M et al (2022) Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial. Circ Heart Fail 15:e10080PubMed
269.
Cunningham JW, Vaduganathan M, Claggett BL (2022) Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. J Am Coll Cardiol 80:1302–1310PubMed
270.
Vardeny O, Fang JC, Desai AS (2022) Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nat Med 28:2504–2511PubMedPubMedCentral
271.
Mc Causland FR, Claggett BL, Vaduganathan M et al (2023) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial. JAMA Cardiol 8:56–65PubMed
272.
Jhund PS, Kondo T, Butt JH et al (2022) Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nat Med 28:1956–1964PubMedPubMedCentral
273.
Kawai Y, Uneda K, Yamada T et al (2022) Comparison of effects of SGLT-2 inhibitors and GLP‑1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with/without albuminuria: a systematic review and network meta-analysis. Diabetes Res Clin Pract 183:109146PubMed
274.
Karagiannis T, Tsapas A, Athanasiadou E et al (2021) GLP‑1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 174:108737PubMed
275.
Bae JH, Park EG, Kim S et al (2021) Comparative renal effects of dipeptidyl peptidase‑4 inhibitors and sodium-glucose cotransporter 2 inhibitors on individual outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. Endocrinol Metab 36:388–400
276.
Palmer SC, Tendal B, Mustafa RA et al (2021) Sodium-glucose cotransporter protein‑2 (SGLT-2) inhibitors and glucagon-like peptide‑1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 372:m4573PubMedPubMedCentral
277.
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128PubMed
278.
Inzucchi SE, Khunti K, Fitchett DH et al (2020) Cardiovascular benefit of empagliflozin across the spectrum of cardiovascular risk factor control in the EMPA-REG OUTCOME trial. J Clin Endocrinol Metab 105:3025–3035PubMedPubMedCentral
279.
McGuire DK, Zinman B, Inzucchi SE et al (2020) Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol 8:949–959PubMed
280.
Wanner C, Inzucchi SE, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334PubMed
281.
Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebocontrolled trial. Lancet Diabetes Endocrinol 5:610–621PubMed
282.
Verma S, Mazer CD, Fitchett D et al (2018) Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: sub-analysis of the EMPA-REG OUTCOME® randomized trial. Diabetologia 61:1712–1723PubMedPubMedCentral
283.
Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424PubMed
284.
Packer M, Anker SD, Butler J et al (2021) Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation 143:326–336PubMed
285.
Anker SD, Butler J, Filippatos G et al (2021) Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation 143:337–349PubMed
286.
Verma S, Dhingra NK, Butler J, EMPEROR-Reduced trial committees and investigators et al (2022) Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. Lancet Diabetes Endocrinol 10:35–45PubMed
287.
Anker SD, Butler J, Filippatos G et al (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385:1451–1461PubMed
288.
Butler J, Filippatos G, Siddiqi TJ et al (2022) Effects of empagliflozin in women and men with heart failure and preserved ejection fraction. Circulation 146:1046–1055PubMedPubMedCentral
289.
Packer M, Butler J, Zannad F, EMPEROR Study Group et al (2021) Empagliflozin and major renal outcomes in heart failure. N Engl J Med 385:1531–1533PubMed
290.
Butler J, Milton Packer M, Filippatos G et al (2022) Effect of Empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J 43:416–426PubMed
291.
Bhm M, Anker S, Mahfoud F (2023) Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. Eur Heart J 44:396–407PubMed
292.
Sharma A, Ferreira JP, Zannad F et al (2023) Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from the EMPEROR-Preserved trial. European J of Heart Fail 25:1337–1348
293.
Kosiborod MN, Angermann CE, Collins SP et al (2022) Effects of empagliflozin on symptoms, physical limitations, and quality of life in patients hospitalized for acute heart failure: results from the EMPULSE trial. Circulation 146:279–288PubMedPubMedCentral
294.
Biegus J, Voors AA, Collins SP (2023) Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J 44:41–50PubMed
295.
Staplin N, Wanner C, The EMPA-KIDNEY Collaborative Group, Herrington WG (2023) Empagliflozin in patients with chronic kidney disease. N Engl J Med 388:117–127PubMed
296.
Alnsasra H, Tsaban G, Solomon A et al (2023) Effect of dapagliflozin versus empagliflozin on cardiovascular death in patients with heart failure across the spectrum of ejection fraction: cost per outcome analysis. Am J Cardiovasc Drugs 23:323–328PubMed
297.
Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425–1435
298.
Rosenstock J, Frias J, Páll D et al (2018) Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab 20:520–529PubMed
299.
Hollander P, Liu J, Hill J et al (2018) Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther 9:193–207PubMed
300.
Cherney DZI, Heerspink HJL, Frederich R et al (2020) Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia 63:1128–1140PubMedPubMedCentral
301.
Cherney DZI, Charbonnel B, Cosentino F, VERTIS CV Investigators (2021) Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia 64:1256–1267PubMedPubMedCentral
302.
Marrs JC, Anderson SL (2020) Ertugliflozin in the treatment of type 2 diabetes mellitus. Drugs Context 9: (2020-7-4)
303.
Dagogo-Jack S, Pratley RE, Cherney DZI et al (2021) Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Res Care 9:e2484PubMedPubMedCentral
304.
Pratley RE, Cannon CP, Cherney DZI (2023) Cardiorenal outcomes, kidney function, and other safety outcomes with ertugliflozin in older adults with type 2 diabetes (VERTIS CV): secondary analyses from a randomised, double-blind trial. Lancet Healthy Longev 4:e143–e154PubMed
305.
Cheng Q, Zou S, Feng C et al (2023) Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Medicine 102:e33198PubMedPubMedCentral
306.
Zhao LM, Huang JN, Qiu M et al (2021) Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases: a meta-analysis of cardiovascular outcome trials. Medicine 100:e27362PubMedPubMedCentral
307.
Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306PubMed
308.
Yu J, Li J, Leaver PJ et al (2021) Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS program and CREDENCE trial. Cardiovasc Res 118:1103–1114
309.
Zhou F, Du N, Zhou L et al (2022) The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: a meta-analysis of randomized trials. Front Endocrinol 13:968478
310.
Bhatt DL, Szarek M, Steg PG et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384:117–128PubMed
311.
Bhatt DL, Szarek M, Pitt B, SCORED investigators et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384:129–139PubMed
312.
Avgerinos I, Karagiannis T, Kakotrichi P et al (2022) Sotagliflozin for patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 24:106–114PubMed
313.
Zhou P, Tan Y, Hao Z et al (2023) Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: a systematic review and meta-analysis. Front Endocrinol 14:1144838
314.
Gu Y, Sun L, Zhang W et al (2023) Comparative efficacy of 5 sodium-glucose cotransporter protein‑2 (SGLT-2) inhibitor and 4 glucagon-like peptide‑1 (GLP-1) receptor agonist drugs in non-alcoholic fatty liver disease: A GRADE-assessed systematic review and network meta-analysis of randomized controlled trials. Front Pharmacol 14:1102792PubMedPubMedCentral
315.
316.
Zou CY, Liu XK, Sang YQ et al (2019) Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes. A metaanalysis. Medicine 98:e18245PubMedPubMedCentral
317.
Salah HM, Al’Aref SJ, Khan MS et al (2021) Effects of sodium-glucose cotransporter 1 and 2 inhibitors on cardiovascular and kidney outcomes in type 2 diabetes: a meta-analysis update. Am Heart J 233:86–91PubMed
318.
Qiu M, Ding L, Zhou H (2021) Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: a meta-analysis with trial sequential analysis. Medicine 100:e25121PubMedPubMedCentral
319.
Yamada T, Wakabayashi M, Bhalla A et al (2021) Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP‑1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol 20:14PubMedPubMedCentral
320.
Li CX, Liang S, Gao L et al (2021) Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: a real-world systematic review and meta-analysis. PLoS ONE 16:e244689PubMedPubMedCentral
321.
Lin FJ, Wang CC, Hsu CN et al (2021) Reno-protective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study. Cardiovasc Diabetol 20:203PubMedPubMedCentral
322.
Lin DS, Lee JK, Hung CS et al (2021) The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia 64:2676–2686PubMed
323.
Teo YH, Yoong CSY, Syn NL et al (2021) Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 77:1453–1464PubMed
324.
Teo YH, Teo YN, Syn NL et al (2021) Effects of Sodium/Glucose Cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc 10:e19463PubMedPubMedCentral
325.
Barbarawi M, Al-Abdouh A, Barbarawi O et al (2022) SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis. Heart Fail Rev 27:951–960PubMed
326.
Giugliano D, Longo M, Scappaticcio L et al (2021) SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol 20:236PubMedPubMedCentral
327.
Giugliano D, Longo M, Caruso P et al (2021) Sodium-glucose cotransporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis. Diabetes Obes Metab 23:1672–1676PubMed
328.
Kaze AD, Zhuo M, Kim SC et al (2022) Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol 21:47231
329.
Yang Q, Lang Y, Yang W et al (2023) Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: a systematic review and network meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 198:110592PubMed
330.
Liu Y, An C, Liu P et al (2023) Comparative safety of sodium-glucose co-transporter 2 inhibitors in elderly patients with type 2 diabetes mellitus and diabetic kidney disease: a systematic review and meta-analysis. Ren Fail 45:2217287PubMedPubMedCentral
331.
Spiazzi BF, Naibo RA, Wayerbacher LF et al (2023) Sodium-glucose cotransporter-2 inhibitors and cancer outcomes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 198:110621PubMed
332.
Sattar N, McLaren J, Kristensen SL et al (2016) SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 59:1333–1339PubMedPubMedCentral
333.
Ferrannini E, Mark M, Mayoux E et al (2016) CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39:1108–1114PubMed
334.
Dutka M, Bobiński R, Ulman-Włodarz I et al (2021) Sodium glucose cotransporter 2 inhibitors: mechanisms of action in heart failure. Heart Fail Rev 26:603–622PubMed
335.
Thomas MC, Cherney DZI (2018) The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure. Diabetologia 61:2098–2210PubMed
336.
Yurista SR, Chong CR, Badimon JJ et al (2021) Therapeutic potenzial of ketone bodies for patients with cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 77:1660–1669PubMed
337.
Levin PA, Nguyen H, Wittbrodt ET et al (2017) Glucagon-like peptide‑1 receptor agonists: a systematic review of comparative effectiveness research. Diabetes Metab Syndr Obes 10:123–139PubMedPubMedCentral
338.
Nauck MA, Kemmeries G, Holst JJ et al (2011) Rapid tachyphylaxis of the glucagon-like peptide 1‑induced deceleration of gastric emptying in humans. Diabetes 60:1561–1565PubMedPubMedCentral
339.
Meier JJ, Rosenstock J, Hincelin-Mery A et al (2015) Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 38:1263–1273PubMed
340.
Drucker DJ, Buse JB, Taylor K et al (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240–1250PubMed
341.
Holman RR, Bethel MA, Mentz RJ et al (2017) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377:1228–1239PubMedPubMedCentral
342.
Fudim M, White J, Pagidipati NJ et al (2019) Effect of Once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes. Insights from the EXSCEL trial. Circulation 140:1613–1622PubMedPubMedCentral
343.
Bonora BM, Avogaro A, Fadini GP (2019) Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol 56:1051–1060PubMed
344.
Jabbour SA, Frías JP, Ahmed A et al (2020) Efficacy and safety over 2 years of exenatide plus dapagliflozin in the DURATION‑8 study: a multicenter, double-blind, phase 3, randomized controlled trial. Diabetes Care 43:2528–2536PubMedPubMedCentral
345.
Bethel MA, Patel RA, Merrill P et al (2018) Cardiovascular outcomes with glucagon-like peptide‑1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 6:105–113PubMed
346.
van der Aart-van der Beek AB, van Raalte DH, Guja C et al (2020) Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: pooled analysis of randomized active controlled clinical trials. Diabetes Obes Metab 22:1556–1566PubMedPubMedCentral
347.
Tamborlane WV, Bishai R, Geller D et al (2022) Once-weekly exenatide in youth with type 2 diabetes. Diabetes Care 45:1833–1840PubMedPubMedCentral
348.
Inaishi J, Saisho Y (2022) Exenatide once weekly for management of type 2 diabetes: a review. Clin Pharmacol 14:19–26PubMedPubMedCentral
349.
Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257PubMed
350.
Home P, Blonde L, Kalra S et al (2020) Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: a systematic review and bayesian network meta-analysis. Diabetes Obes Metab 22:2179–2188PubMed
351.
Ferrannini E, Niemoeller E, Dex T et al (2022) Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves β‑cell function in people with type 2 diabetes. Diabetes Obes Metab 24:1159–1165PubMedPubMedCentral
352.
Polonsky WH, Giorgino F, Rosenstock J et al (2022) Improved patient-reported outcomes with 258].in people with type 2 diabetes in the soliMix trial. Diabetes Obes Metab 24:2364–2372PubMedPubMedCentral
353.
Lundgren JR, Janus C, Jensen SBK et al (2021) Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 384:1719–1730PubMed
354.
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322PubMedPubMedCentral
355.
Verma S, Bhatt DL, Bain SC et al (2018) Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease. Circulation 137:2179–2183PubMed
356.
Marso SP, Nauck MA, Monk Fries T et al (2018) Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the LEADER Trial). Am J Cardiol 121:1467–1470PubMed
357.
Duan CM, Wan TF, Wang Y et al (2019) Cardiovascular outcomes of liraglutide in patients with type 2 diabetes. A systematic review and meta-analysis. Medicine 98:e17860PubMedPubMedCentral
358.
Mann JFE, Ørsted DD, Buse JB (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377:839–848PubMed
359.
Shaman AM, Bain SC, Bakris GL et al (2022) Effect of the glucagon-like peptide‑1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation 145:575–585PubMed
360.
Heller SR, Geybels MS, Iqbal A et al (2022) A higher non-severe hypoglycaemia rate is associated with an increased risk of subsequent severe hypoglycaemia and major adverse cardiovascular events in individuals with type 2 diabetes in the LEADER study. Diabetologia 65:55–64PubMed
361.
Unger J, Allison DC, Kaltoft M et al (2022) Maintenance of glycaemic control with liraglutide versus oral antidiabetic drugs as add-on therapies in patients with type 2 diabetes uncontrolled with metformin alone: A randomized clinical trial in primary care (LIRA-PRIME). Diabetes Obes Metab 24:204–211PubMed
362.
Kristensen SL, Rørth R, Jhund PS (2019) Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:776–785PubMed
363.
Liu J, Li L, Deng K et al (2017) Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ 357:j2499PubMedPubMedCentral
364.
Pasternak B, Wintzell V, Eliasson B et al (2020) Use of glucagon like peptide 1 receptor agonists and risk of serious renal events: Scandinavian cohort study. Diabetes Care 43:1326–1335PubMed
365.
Nathan DM, Lachin JM, Balasubramanyam A, GRADE Study Research Group et al (2022) Glycemia reduction in type 2 diabetes—glycemic outcomes. N Engl J Med 387:1063–1074PubMed
366.
Nathan DM, Lachin JM, Bebu I, GRADE Study Research Group et al (2022) Glycemia reduction in type 2 diabetes—microvascular and cardiovascular outcomes. N Engl J Med 387:1075–1088PubMed
367.
He F, Chen W, Xu W et al (2023) Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 25:664–674PubMed
368.
Mac Isaac RJ (2020) Dulaglutide and Insulin: How can the AWARD studies help guide clinical practice? Diabetes Ther 11:1627–1638PubMed
369.
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomized, placebo-controlled trial. Lancet 394:131–138PubMed
370.
Dagenais GR, Rydén L, Leiter LA et al (2020) Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovasc Diabetol 19:199PubMedPubMedCentral
371.
Ferrannini G, Gerstein H, Colhoun HM et al (2021) Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. Eur Heart J 42:2565–2573PubMed
372.
Branch KRH, Dagenais GR, Avezum A et al (2022) Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial. European J of Heart Fail 24:1805–1812
373.
Arslanian SA, Hannon T, Zeitler P, AWARD-PEDS Investigators. et al (2022) Once-weekly dulaglutide for the treatment of youths with type 2 diabetes. N Engl J Med 387:433–443PubMed
374.
Mishriky BM, Cummings DM, Powell JR et al (2019) Comparing once weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab 45:102–109PubMed
375.
Wilding JPH, Batterham RL, Calanna S, STEP 1 Study Group et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989–1002PubMed
376.
Wadden TA, Bailey TS, Billings LK, STEP 3 Investigators et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325:1403–1413PubMed
377.
Rubino D, Abrahamsson N, Davies M, STEP 4 Investigators et al (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325:1414–1425PubMed
378.
Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844PubMed
379.
Leiter LA, Bain SC, Hramiak I et al (2019) Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol 18:73PubMedPubMedCentral
380.
Stretton B, Kovoor J, Bacchi S et al (2023) Weight loss with subcutaneous semaglutide versus other glucagon like peptide‑1 receptor agonists In type 2 diabetes: a systematic review. Intern Med J 53:1311–1320PubMed
381.
Husain M, Birkenfeld AL, Donsmark M, PIONEER 6 Investigators et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841–851PubMed
382.
Avgerinos I, Michailidis T, Liakos A et al (2020) Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 22:335–345PubMed
383.
Aroda VR, Bauer R, Christiansen E (2022) Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme. Diabetes Obes Metab 24:1338–1350PubMedPubMedCentral
384.
Husain M, Bain SC, Holst AG et al (2020) Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovasc Diabetol 19:156PubMedPubMedCentral
385.
Nauck MA, Quast DR (2021) Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol 12:645566
386.
Dicembrini I, Nreu B, Scatena A et al (2017) Microvascular effects of glucagon-like peptide‑1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials. Acta Diabetol 54:933–941PubMed
387.
Mann JFE, Hansen T, Idorn T et al (2020) Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol 8:880–893PubMed
388.
Hammerman A, Moore CM, Aboalhasan E (2022) Usefulness of empagliflozin versus oral semaglutide for prevention of cardiovascular mortality in patients with type 2 diabetes mellitus. Am J Cardiol 170:128–131PubMed
389.
Li A, Su X, Hu S, Wang Y (2023) Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 198:110605PubMed
390.
Strain WD, Frenkel O, James MA et al (2022) Effects of semaglutide on stroke subtypes in type 2 diabetes: post hoc analysis of the randomized SUSTAIN 6 and PIONEER 6. Stroke 53:2749–2757PubMedPubMedCentral
391.
Banerjee M, Pal R, Mukhopadhyay S et al (2023) GLP‑1 receptor agonists and risk of adverse cerebrovascular outcomes in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. J Clin Endocrinol Metab 108:1806–1812PubMed
392.
Home PD, Ahrén B, Reusch JEB et al (2017) Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: longterm efficacy with or without rescue therapy. Diabetes Res Clin Pract 131:49–60PubMed
393.
Ahrén B, Carr MC, Murphy K et al (2017) Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials. Diabetes Res Clin Pract 126:230–239PubMed
394.
Hernandez AF, Green JB, Janmohamed S et al (2018) Harmony outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomized placebo-controlled trial. Lancet 392:1519–1529PubMed
395.
Rosenstock J, Nino A, Soffer J et al (2020) Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial. Diabetes Care 43:2509–2518PubMedPubMedCentral
396.
Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 385:896–907PubMed
397.
Lam CSP, Ramasundarahettige C, Branch KRH (2022) Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter‑2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE‑O trial. Circulation 145:565–574PubMed
398.
Gerstein HC, Li Z, Ramasundarahettige C et al (2023) Exploring the relationship between efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: insights from the AMPLITUDE‑O trial. Circulation 147:1004–1013PubMed
399.
Coskun T, Sloop KW, Loghin C et al (2018) LY3298 176, a novel dual GIP and GLP‑1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab 18:3–14PubMedPubMedCentral
400.
Zhao F, Zhou Q, Cong Z et al (2022) Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP‑1 or glucagon receptors. Nat Commun 13:1057ADSPubMedPubMedCentral
401.
Frias JP, Nauck MA, Van Joanna et al (2020) Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide‑1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebocontrolled study to evaluate different dose-escalation regimens. Diabetes Obes Metab 22:938–946PubMedPubMedCentral
402.
Nauck MA, Wefers J, Meier JJ (2021) Treatment of type 2 diabetes: challenges, hopes, and anticipated successes. Lancet Diabetes Endocrinol 9:525–544PubMed
403.
Rosenstock J, Wysham C, Frías JP et al (2021) Efficacy and safety of a novel dual GIP and GLP‑1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398:143–155PubMed
404.
Frías JP, Davies MJ, Rosenstock J (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes; SURPASS‑2 investigators. N Engl J Med 385:503–515PubMed
405.
Hartman ML, Sanyal AJ, Loomba R et al (2020) Effects of novel dual GIP and GLP‑1 receptor agonist tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes. Diabetes Care 43:1352–1355PubMedPubMedCentral
406.
Wilson JM, Nikooienejad A, Robins DA et al (2020) The dual glucosedependent insulinotropic peptide andglucagon-like peptide‑1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes Obes Metab 22:2451–2459PubMedPubMedCentral
407.
Sattar N, McGuire DK, Pavo I (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 28:591–598PubMedPubMedCentral
408.
Dutta D, Surana V, Singla R et al (2021) Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP‑1 receptor agonist in the management of type‑2 diabetes: a cochrane meta-analysis. Indian J Endocrinol Metab 25:475–489PubMed
409.
Rodriguez-Valadez JM, Tahsin M, Fleischmann KE et al (2023) Cardiovascular and renal benefits of novel diabetes drugs by baseline cardiovascular risk: a systematic review, meta-analysis, and meta-regression. Diabetes Care 46:1300–1310PubMed
410.
Vilsbøll T, Bain SC, Leiter LA et al (2018) Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 20:889–897PubMedPubMedCentral
411.
Sattar N, Lee MMY, Kristensen S et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP‑1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9:653–662PubMed
412.
Bethel MA, Diaz R, Castellana N (2021) HbA1c change and diabetic retinopathy during GLP‑1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care 44:290–296PubMed
413.
Wang F, Mao Y, Wang H et al (2022) Semaglutide and diabetic retinopathy risk in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Clin Drug Investig 42:17–28PubMed
414.
Gaborit B, Julla JB, Besbes S et al (2020) Glucagon-like peptide 1 receptor agonists, diabetic retinopathy and angiogenesis: the angioSafe type 2 diabetes study. J Clin Endocrinol Metab 105:dgz69PubMed
415.
Yoshida Y, Joshi P, Barri S et al (2022) Progression of retinopathy with glucagon-like peptide‑1 receptor agonists with cardiovascular benefits in type 2 diabetes—a systematic review and meta-analysis. J Diabetes Complications 36:108255PubMed
416.
Monami M, Nreu B, Scatena A et al (2017) Safety issues with glucagon-like peptide‑1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab 19:1233–1241PubMed
417.
Abd El Aziz M, Cahyadi O, Meier JJ et al (2020) Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab 22:699–704PubMed
418.
Cao C, Yang S, Zhou Z (2019) GLP‑1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine 66:157–165PubMed
419.
Azoulay L, Filion KB, Platt RW et al (2016) Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med 176:1464–1473PubMed
420.
Wang T, Wang F, Gou Z et al (2015) Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324 515 patients from observational studies. Diabetes Obes Metab 17:32–41PubMed
421.
Ueda P, Wintzell V, Melbye M et al (2021) Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study. Diabetologia 64:2204–2214PubMedPubMedCentral
422.
Piccoli GF, Mesquita LA, Stein C et al (2021) Do GLP‑1 receptor agonists Increase the risk of breast cancer? A systematic review and meta-analysis. J Clin Endocrinol Metab 106:912–921PubMed
423.
Hidayat K, Zhou YY, Du HZ et al (2023) A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer. Pharmacoepidemiol Drug Saf 32:107–125PubMed
424.
Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113–1124PubMed
425.
Gastaldelli A, Cusi K, Fernández LL (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS‑3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10:393–406PubMed
426.
Mantsiou C, Karagiannis T, Kakotrichi P et al (2020) Glucagon-like peptide‑1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 22:1857–1868PubMed
427.
Wright AK, Carr MJ, Kontopantelis E (2022) Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP‑1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care 45:909–918PubMed
428.
Russell-Jones D, Pouwer F, Khunti K (2018) Identification of barriers to insulin therapy and approaches to overcoming them. Diabetes Obes Metab 20:488–496PubMed
429.
Landgraf R, Aberle J (2021) Hundert Jahre – Insulin bleibt aktuell und notwendig. Diabetologie 16:1–13
430.
Retnakaran R, Zinman B (2022) The ongoing evolution of basal insulin therapy over 100 years and its promise for the future. Diabetes Obes Metab 24(Suppl 1):17–26PubMed
431.
Bolli GB, Porcellati F, Lucidi P et al (2022) One-hundred years evolution of prandial insulin preparations: from animal pancreas extracts to rapid-acting analogs. Metabolism 126:15435
432.
Marso SP, McGuire DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377:723–732PubMedPubMedCentral
433.
Pieber TR, Marso SP, McGuire DK et al (2018) DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. Diabetologia 61:58–65PubMed
434.
Lau IT, Lee KF, So WY et al (2017) Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus. Diabetes Metab Syndr Obes 10:273–284PubMedPubMedCentral
435.
Ritzel R, Roussel R, Giaccari A et al (2018) Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‑year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes. Diabetes Obes Metab 20:541–548PubMed
436.
Bonadonna RC, Renard E, Cheng A et al (2018) Switching to insulin glargine 300 U/mL: Is duration of prior basal insulin therapy important? Diabetes Res Clin Pract 142:19–25PubMed
437.
Blonde L, Bailey T, Sullivan SD et al (2021) Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: a review of the DELIVER programme. Diabetes Obes Metab 23:1713–1721PubMedPubMedCentral
438.
Linnebjerg H, Lam EC, Seger ME et al (2015) Comparison of the pharmacokinetics and pharmacodynamics of LY2963 016 insulin glargine and EU and US-approved versions of lantus insulin glargine in healthy subjects: Three randomized euglycemic clamp studies. Diabetes Care 38:2226–2233PubMed
439.
Rosenstock J, Hollander P, Bhargava A et al (2015) Similar efficacy and safety of LY2963 016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, doubleblind controlled trial (ELEMENT 2 study). Diabetes Obesity Metabolism 17:734–741PubMed
440.
Yamada T, Kamata R, Ishinohachi K et al (2018) Biosimilar vs originator insulins: systematic review and meta-analysis. Diabetes Obes Metab 20:1787–1792PubMed
441.
But A, De Bruin ML, Bazelier MT et al (2017) Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia 60:1691–1703PubMedPubMedCentral
442.
Nauck MA, Mirna AEA, Quast DR (2023) Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: an update including recently developed glucagon-like peptide‑1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP‑1 receptor co-agonist tirzepatide. Diabetes Obes Metab 25:1361–1371PubMed
443.
Nishimura E, Pridal L, Glendorf T (2021) Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care 9:e2301PubMedPubMedCentral
444.
Rosenstock J, Bajaj HS, Janež A, NN1436–4383 Investigators. (2020) Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med 383:2107–2116PubMed
445.
Bajaj HS, Bergenstal RM, Christoffersen A et al (2021) Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care 44:1586–1594PubMedPubMedCentral
446.
Mathieu C, Ásbjörnsdóttir B, Bajaj HS et al (2023) Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet 401:1929–1940PubMed
447.
Silva RER, de Miranda Gauza M, Schramm Guisso ME et al (2023) Once-weekly insulin Icodec vs. Once-daily insulin glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials. Arch Endocrinol Metab 67:e000 614
448.
Philis-Tsimikas A, Asong M, Franek E et al (2023) Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol 11:414–425PubMed
449.
Maiorino MI, Chiodini P, Bellastella G et al (2017) Insulin and glucagon-like peptide1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care 40:614–624PubMed
450.
Guja C, Frías JP, Somogyi A et al (2018) Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION‑7 randomized study. Diabetes Obes Metab 20:1602–1161PubMedPubMedCentral
451.
Rodbard HW, Lingvay I, Reed J et al (2018) Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab 103:2291–2301PubMedPubMedCentral
452.
Huthmacher JA, Meier JJ, Nauck MA (2020) Efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists on a background of basal insulin in type 2 diabetes: a metaanalysis. Diabetes Care 43:2303–2312PubMed
453.
Rosenstock J, Emral R, Sauque-Reyna L, SOLIMIx Trial investigators et al (2021) Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: clinical outcomes with iGlarLixi versus premix BIAsp 30 in the soliMix randomized controlled trial. Diabetes Care 44:2361–2370PubMedPubMedCentral
454.
Gentile S, Fusco A, Colarusso S et al (2018) A randomized, openlabel, comparative, crossover trial on preference, efficacy, and safety profiles of lispro insulin U‑100 versus concentrated lispro insulin U‑200 in patients with type 2 diabetes mellitus: a possible contribution to greater treatment adherence. Expert Opin Drug Saf 17:445–450PubMed
455.
Heise T, Hövelmann U, Brøndsted L et al (2015) Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab 17:682–688PubMedPubMedCentral
456.
Bowering K, Case C, Harvey J et al (2017) Faster aspart versus insulin aspart as part of a basal-bolus regimen in inadequately controlled type 2 diabetes: the ONSET 2 trial. Diabetes Care 40:951–957PubMed
457.
Heise T, Piras de Oliveira C, Juneja R et al (2022) What is the value of faster acting prandial insulin? Focus on ultra-rapid lispro. Diabetes Obes Metab: 1–13
458.
Leohr J, Kazda C, Liu R et al (2022) Ultra-rapid lispro shows faster pharmacokinetics and reduces postprandial glucose excursions versus humalog® in patients with type 2 diabetes mellitus in a randomized, controlled crossover meal test early phase study. Diabetes Obes Metab 24:187–195PubMed
459.
Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung, 1. Auflage. Version 4. 2013, zuletzt geändert: November 2014. doi: 0.6101/AZQ/000213
460.
Forbes AK, Suckling RJ, Hinton W et al (2023) Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: a systematic review and meta-analysis of observational studies. Diabetes Obes Metab 25:2310–2330PubMed
461.
Karagiannis T, Avgerinos I, Liakos A et al (2022) Management of type 2 diabetes with the dual GIP/GLP‑1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 17:1–11
462.
463.
Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a doubleblind, randomised placebo-controlled trial. Lancet 394:121–130PubMed
Metadaten
Titel
Therapie des Typ-2-Diabetes
verfasst von
Prof. Dr. med. Rüdiger Landgraf
Jens Aberle
Andreas L. Birkenfeld
Baptist Gallwitz
Monika Kellerer
Harald H. Klein
Dirk Müller-Wieland
Michael A. Nauck
Tobias Wiesner
Erhard Siegel
Publikationsdatum
30.01.2024
Verlag
Springer Medizin
Erschienen in
Die Diabetologie / Ausgabe 2/2024
Print ISSN: 2731-7447
Elektronische ISSN: 2731-7455
DOI
https://doi.org/10.1007/s11428-023-01144-y

Weitere Artikel der Ausgabe 2/2024

Die Diabetologie 2/2024 Zur Ausgabe

Einführung zum Thema

Pathophysiologie des Typ-2-Diabetes

DDG Praxisempfehlungen

Diabetes mellitus und Herz

Mitteilungen des BDE

Mitteilungen des BDE

Leitthema

Ursachen, Klinik und Folgen der Insulinresistenz bei Typ-2-Diabetes

Leitthema

Wechselwirkung zwischen eingeschränkter Insulinsekretionskapazität und Insulinresistenz

CME

CME: Gefäßerkrankungen bei Diabetes mellitus

Praxisempfehlungen der Deutschen Diabetes Gesellschaft

Kurz, prägnant und aktuell: Die Praxisempfehlungen der Deutschen Diabetes Gesellschaft. 

Zu den Praxisempfehlungen
Bildnachweise